Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report
- PMID: 23957539
- DOI: 10.3109/00365548.2013.822093
Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report
Abstract
The ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources